Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Major bleeding · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in major bleeding ( compared with control (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
Major bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in major bleeding compared with inpatient treatment (low certainty).
2 findings from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Intervention not reported
Major bleeding ( · patients with less than 42 days' lower limb ischaemia
It is very uncertain whether the intervention changes major bleeding ( (very low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists may leads to higher bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found